Skip to main content
. 2025 May 17;17(5):661. doi: 10.3390/pharmaceutics17050661
amyloid-beta
AD Alzheimer’s disease
Ang-2 Angiopep-2
AMT adsorptive-mediated transcytosis
ApoE3 Apolipoprotein E3
ApoE-SLNs ApoE-functionalized solid lipid NPs
BBB blood–brain barrier
BCECs brain capillary endothelial cells
BDNF brain-derived neurotrophic factor
BTE brain tumor-related epilepsy
CAGR compound annual growth rate
CBD cannabidiol
CNS central nervous system
CPP cell-penetrating peptide
CRT cyclic CRTIGPSVC
Cur curcumin
DOX doxorubicin
DXT docetaxel
EMA European Medicines Agency
FA folic acid
FUS focused ultrasound
Gb3 globotriaosylceramide
GMP Good Manufacturing Practice
HA hyaluronic acid
HSA human serum albumin
LDL low-density lipoprotein
Lf lactoferrin
LfR lactoferirn receptors
LPS lipopolysaccharide
LRP-1 lipoprotein receptor-related protein 1
nAChR nicotinic acetylcholine receptor
NGF nerve growth factor
NLCs nanostructured lipid carriers
NPs nanoparticles
mAb monoclonal antibody
MYR myricetin
PBCECs porcine brain capillary endothelial cells P
pBDNF BDNF plasmid
PCB polycarboxybetaine
PEG polyethylene glycol
PLGA polylactic-co-glycolic acid
PTX paclitaxel
ROS reactive oxygen species
RVG rabies virus glycoprotein
SHK shikonin
scFv single-chain variable fragment
siRNA interfering RNA
SLNs solid lipid nanoparticles
STxB shiga toxin B
TAT transactivator of transcription peptide
Tf transferrin
TfRs transferrin receptors
TMC N-trimethyl chitosan
TTF tumor-treating fields